We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current APLI market cap is 132.18M. The company's latest EPS is CAD -0.0312 and P/E is -0.96.
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 643k | 660k | 1.65M | 383k | 6.69M |
| Operating Income | -5.44M | -14.38M | -23.61M | -7.76M | -2.15M |
| Net Income | -5.42M | -14.33M | -25.12M | -9.24M | -3.78M |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 11.17M | 18.32M | 8.28M | 3.13M | 1.49M |
| Total Liabilities | 2.33M | 5.56M | 11.55M | 10.53M | 12.42M |
| Total Equity | 8.85M | 12.75M | -3.27M | -7.4M | -10.93M |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -4.26M | -11.45M | -19.08M | -10.1M | -2.46M |
| Investing | -1,000 | -4.99M | 5.06M | -3k | -29k |
| Financing | 9.36M | 17.02M | 9.56M | 5.91M | 122k |
| Market Cap | 132.18M |
| Price to Earnings Ratio | -0.96 |
| Price to Sales Ratio | 0.54 |
| Price to Cash Ratio | 37.5 |
| Price to Book Ratio | -0.33 |
| Dividend Yield | - |
| Shares Outstanding | 121.27M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.02 (1.83%) |
| Company Name | Appili Therapeutics Inc |
| Address |
21-1344 summer street halifax, nova scotia B3H 0A8 |
| Website | https://www.appilitherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
